Inventiva at Canaccord Genuity 45th Annual Growth Conference

Inventiva, a Daix-based biopharmaceutical company specializing in the treatment of metabolic steatohepatitis (MASH), announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The event will take place in Boston from August 12 to 14, 2025.

Jason Campagna, President of R&D and Chief Medical Officer, and David Nikodem, Vice President of US Operations, will represent the company during a fireside chat. The program will include a presentation of the latest therapeutic advances, including lanifibranor and the NATiV3 Phase III clinical trial in MASH, as well as a discussion on Inventiva's R&D strategy.